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Abstract
Introduction: Protein tyrosine kinases (PTKs) are frequently overexpressed and/or activated in human malignancies,
and regulate cancer cell proliferation, cellular survival, and migration. As such, they have become promising
molecular targets for new therapies. The non-receptor PTK termed breast tumor kinase (Brk/PTK6) is overexpressed
in approximately 86% of human breast tumors. The role of Brk in breast pathology is unclear.
Methods: We expressed a WAP-driven Brk/PTK6 transgene in FVB/n mice, and analyzed mammary glands from
wild-type (wt) and transgenic mice after forced weaning. Western blotting and immunohistochemistry (IHC) studies
were conducted to visualize markers of mammary gland involution, cell proliferation and apoptosis, as well as Brk,
STAT3, and activated p38 mitogen-activated protein kinase (MAPK) in mammary tissues and tumors from WAP-Brk
mice. Human (HMEC) or mouse (HC11) mammary epithelial cells were stably or transiently transfected with Brk
cDNA to assay p38 MAPK signaling and cell survival in suspension or in response to chemotherapeutic agents.
Results: Brk-transgenic dams exhibited delayed mammary gland involution and aged mice developed infrequent
tumors with reduced latency relative to wt mice. Consistent with delayed involution, mammary glands of
transgenic animals displayed decreased STAT3 phosphorylation, a marker of early-stage involution. Notably, p38
MAPK, a pro-survival signaling mediator downstream of Brk, was activated in mammary glands of Brk transgenic
relative to wt mice. Brk-dependent signaling to p38 MAPK was recapitulated by Brk overexpression in the HC11
murine mammary epithelial cell (MEC) line and human MEC, while Brk knock-down in breast cancer cells blocked
EGF-stimulated p38 signaling. Additionally, human or mouse MECs expressing Brk exhibited increased anchorage-
independent survival and resistance to doxorubicin. Finally, breast tumor biopsies were subjected to IHC analysis
for co-expression of Brk and phospho-p38 MAPK; ductal and lobular carcinomas expressing Brk were significantly
more likely to express elevated phospho-p38 MAPK.
Conclusions: These studies illustrate that forced expression of Brk/PTK6 in non-transformed mammary epithelial
cells mediates p38 MAPK phosphorylation and promotes increased cellular survival, delayed involution, and latent
tumor formation. Brk expression in human breast tumors may contribute to progression by inducing p38-driven
pro-survival signaling pathways.
* Correspondence: lange047@umn.edu
1Department of Medicine (Division of Hematology, Oncology, and
Transplantation), University of Minnesota, 420 Delaware St. SE, MMC 806,
Minneapolis, MN 55455, USA
Full list of author information is available at the end of the article
Lofgren et al. Breast Cancer Research 2011, 13:R89
http://breast-cancer-research.com/content/13/5/R89
© 2011 Lofgren et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
Total protein tyrosine kinase (PTK) activity is elevated
in breast cancer [1] and this condition is associated with
poor prognosis [2]. PTKs and their downstream signal-
ing pathways contribute to critical biological functions
relevant to the cancerous phenotype, such as increased
cellular proliferation, pro-survival, invasion and migra-
tion/metastasis. One such cancer-associated PTK is
breast tumor kinase/protein tyrosine kinase 6 (Brk/
PTK6). Brk was cloned in a screen for tyrosine kinases
expressed in a metastatic breast tumor [3]. The murine
Brk-ortholog, Src-like intestinal kinase (Sik), was inde-
pendently cloned from the small intestine and skin and
found to share 80% identity with Brk [4]. Although con-
s i d e r e dt ob eo n l yd i s t a n t l yrelated to c-Src, Brk shares
a similar domain structure, consisting of an N-terminal
SH2 domain, an SH3 domain, and a C-terminal kinase
domain that is subject to autophosphorylation and auto-
inhibition [5]. However, the Brk C-terminus lacks a
motif required for myristoylation (that is, as found in c-
Src), rendering it truly “soluble” or mobile within and
between cellular compartments [3,4].
Brk is overexpressed in up to 86% of invasive ductal
breast carcinomas [6,7], prostate and colon carcinomas
[8,9], 70% of serous ovarian carcinomas [10], 37.5% of a
limited sampling of head and neck squamous cell carci-
nomas [11], and a small percentage of metastatic melano-
mas [12]. Brk expression levels increase in association
with the carcinoma content of breast tumors [7], tumor
grade [13], and invasiveness of breast cancer cell lines
[14]. Normal tissues that express Brk include the intest-
inal epithelium, melanocytes, keratinocytes [4,15], pros-
tate luminal epithelium [16], and lymphocytes [17].
However, Brk appears to be absent from normal mam-
mary tissue [8]. The list of Brk substrates and interacting
proteins is limited, but consists largely of signaling or sig-
nal transduction-related adaptor molecules, and RNA- or
DNA-binding proteins, including signal transducers and
activators of transcription( S T A T s ) .N o t a b l y ,b o t h
STAT3 and STAT5b have been shown to be direct sub-
strates of Brk in vitro [18,19]. These molecules are also
required regulators of mammary gland lactogenic differ-
entiation (STAT5, [20]) and regression (STAT3, [21]).
Mammary gland development is a highly dynamic and
hormonally-driven process; functional glands are not
fully mature until early adulthood or pregnancy. Begin-
ning as an invagination of dermal epithelium (that is, in
the embryo), the mammary anlage migrates into the
mesenchyme, eventually elongating into a rudimentary
branched ductal tree [22]. The gland remains at this pri-
mitive state until puberty, when the terminal end buds
(TEBs) respond to hormonal cues and lead the advance-
ment and secondary branching of the ductal network
further into the mammary fat pad resulting in a network
of hollow ducts. Outside of fluctuations in secondary
branching due to cycling hormonal cues during the
estrous cycle [22], further functional differentiation is
temporarily halted until pregnancy. Upon pregnancy, a
marked increase in ductal branching and alveolar prolif-
eration and differentiation occurs, preparing the gland
for lactogenesis.
Once the suckling stimulus of the offspring is
removed, involution is initiated. In mouse models, com-
pletion of this regressive 10-day process returns the
gland to a near virgin state. Post-lactational involution is
characterized by events that can be classified into two
distinct stages. First, milk stasis and the resulting
mechanical stresses initiate a tightly regulated wave of
apoptosis in alveolar epithelial cells and their concomi-
tant removal [23], followed by the second stage in which
remodeling of the ECM and the expansion of the stro-
mal adipocyte compartment occurs [24]. Mouse models
have been extensively used to understand genetic
mechanisms of breast cancer biology [25]. Indeed, classi-
cal models of human breast oncogene overexpression in
the mouse mammary gland demonstrate altered biologi-
cal processes responsible for proper ductal and alveolar
development, as well as modified initiation and execu-
tion of glandular involution [26].
In this study, we describe the first transgenic model of
mammary gland specific (that is, WAP-promoter-driven)
Brk expression. Using newly created Brk-WAP trans-
genic mice, we studied the physiological process of
mammary gland involution to investigate the impact of
Brk expression on the survival of mammary luminal
epithelium, and altered regulation of pro-survival signal-




Transgenic mice expressing the human Brk/PTK6 gene
under the control of the whey acidic protein (WAP)
promoter were generated by microinjection of a WAP-
Brk insert containing the wild-type Brk cDNA under the
control of the WAP gene promoter into FVB/n embryos
(University of MN Mouse Genetics Laboratory). The
Brk cDNA was subcloned into the WKbpAII vector (a
kind gift of Dr. Jeff Rosen, Baylor College of Medicine;
[27]) using EcoR1 sites within the multiple cloning
sequence. Two founders (one female, one male) were
identified by PCR screening of tail biopsy DNA, and
confirmed by Southern blotting (data not shown). Pri-
mer sequences for genotyping transgenic animals (by
collection of DNA harvested from tail biopsies) span the
Brk coding sequence (sense, 5’-agcgtgcacaagctgatgct-3’)
and the bovine growth hormone poly-A region of the
transgene (antisense, 5’-tctctggctgtctgtctgca-3’).
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nesota IACUC approved protocols and NIH guidelines.
Involution timecourse
Virgin FVB/n or WAP-Brk mice were bred; litters were
carried to term and normalized to eight pups upon par-
turition. Pups were nursed for 10 days at which time
the litter was force weaned. Mammary glands were har-
vested at one day post-weaning; involution Day 1
(INV1), INV4, INV6, INV9, and INV14.
Whole mounts
Inguinal mammary glands were harvested and fixed,
washed with PBS and stained with Carmine Alum.
Glands were then dehydrated in graded ethanols, cleared
with xylenes, and affixed to slides.
IHC and differential stains
A Leica Microsystems 1020 automated processor was
used to process tissues after fixation. After paraffiniza-
tion, three- to five-micron thick sections were cut and
mounted on slides.
Imaging and analysis
Digital images were taken of three fields per gland from
three glands at 200 × or 400 × total magnification. For
epithelial content determination, a grid of 360 boxes
w a so v e r l a i do n2 0 0×i m a g e sa n db o x e sc o n t a i n i n g
epithelial cells were counted. For IHC quantification,
NIH ImageJ [28] was used with a cell counter plug-in to
manually count positively stained mammary epithelial
cells vs. total epithelial cells in multiple fields. Anno-
tated regions were drawn on each digital H&E image
using a pen tablet (Intuos3, Wacom, Kazo-shi, Saitama,
Japan) for area calculations by determining epithelial
pixel count relative to the entire gland, and selecting
regions of interest for digital IHC analysis. For digital
IHC quantification, slides were scanned at 40 × magnifi-
cation (0.25 microns/pixel) using a whole slide scanner
(ScanScope CS, Aperio Technologies, Vista, CA, USA)
fitted with a 20x/0.75 Plan Apo objective lens (Olympus,
Center Valley, PA, USA). Images were saved in SVS for-
mat (Aperio) compressed with JPG2000 at 70% quality
and retrieved from a secure server using whole slide
image management software (Spectrum, Aperio).
For automated quantification of molecules visualized
by IHC, five annotated regions were drawn on each
slide using a pen tablet screen (Cintiq 21UX, Wacom,
Kazo-shi, Saitama, Japan) on whole slide images viewed
at high resolution using the Aperio system’s annotation
software (ImageScope 10, Aperio).
To detect individual cells in tissue sections, a nuclear
cell quantification image analysis algorithm (IHC Nuclear
Quantification, Aperio) was trained on control slides by
defining the color vectors for the hematoxylin nuclear
counterstain and primary positive chromagen DAB, mini-
mum and maximum size for nuclei, and threshold ranges
for intensity of nuclear staining. The analysis algorithm
was trained to detect nuclei in four intensity ranges for
cells with no positive staining, weak positive staining,
medium positive staining, and strong positive staining.
Analyses were performed on each annotated region using
defined settings and nuclear count results were collected
from each slide. Data were represented as an H-score
[29], which accounts for staining intensity and percentage
of positively stained cells. The H-score = (% of 0 intensity
staining nuclei*0) + (% of 1 intensity staining nuclei)*1 +
(% of 2 intensity staining nuclei)*2 + (% of 3 intensity
staining nuclei) *3. Each H-score represents five fields
each from three mice per time point.
Mammary epithelial cell enrichment
Mammary glands were harvested and weighed. Follow-
ing disruption with scalpels, tissue homogenates were
incubated at 37°C in digestion buffer (Ham’sF 1 2 /
DMEM, 2 mg/mL collagenase A (Roche, Indianapolis,
IN, USA), 100 U/ml hyaluronidase (Sigma-Aldrich, St.
Louis, MO USA)). Digested mammary tissue was pel-
leted and washed with Ham’s F12/DMEM+1% serum
three times at 1, 500 rpm, then twice at 800 rpm. Cell
pellets were lysed as in [30] with the addition of Roche
PhosStop and Complete tablets.
Immunohistochemistry (IHC)
Formalin fixed paraffin embedded (FFPE) sections of
mammary glands were deparaffinized with xylenes, and
rehydrated through graded alcohols (70% to 100%).
Rehydrated sections were equilibrated in PBS and
microwaved in antigen retrieval buffer (10 mM sodium
citrate, pH 6.0 for 20 minutes or 1 mM EDTA, pH 8.0
for 10 minutes). Slides were washed with ddH2O then
PBS and placed in 3% H2O2 for 10 minutes to block
endogenous peroxidases.
Sections blocked with serum-free protein block (Dako
X0909) were incubated overnight at 4°C with primary
antibodies diluted in Dako Antibody Diluent (S0809),
washed with PBST and incubated in biotinylated sec-
ondary antibody (Vector Laboratories Vectastain Elite
Kit, PK-101) for 30 minutes at room temperature. Slides
were washed, then incubated with Vectastain Elite RTU
ABC reagent (PK-7100) and subjected to colorimetric
detection with ImmPACT DAB substrate (Vector
Laboratories, SK-4105). Antibodies used for IHC are as
follows: Brk was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA); phospho-p38 mitrogen-acti-
vated protein kinase (MAPK), phospho-STAT3,
phospho-STAT5, and cleaved caspase 3 were purchased
from Cell Signaling (Danvers, MA, USA).
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HC11 murine mammary epithelial cells were plated and
transfected with pCMV-3X-FL-Brk constructs using
FuGene HD (Roche), serum starved post-transfection,
and treated with 500 ng/mL prolactin (Sigma). HMEC-
Brk and T47D shRNA stable cell lines described pre-
viously [7,31] were treated with 25 ng/mL epidermal
growth factor (Sigma). Cells were lysed as previously
described [30]. Immunoblotting was performed with Brk
(Santa Cruz, in-house antibody), total and phospho
STAT5 and total and phospho-p38 MAPK (Cell Signal-
ing), and E-cadherin antibodies.
Anchorage independence
Six-well dishes were coated with PolyHEMA (20 mg/mL
in 98% EtOH) and dried in an incubator overnight. Pre-
viously described HMEC+Brk cells [31] or HC11 cells
transiently transfected with Brk (as above) were plated
at a density of 300 K cells per well, and maintained in
culture for 48 hr. Cells in suspension were collected,
trypsinized and stained with 0.4% Trypan Blue. Viable
cells from each sample were counted in triplicate.
Tissue microarray
A series of human breast tissue samples surgically
obtained from healthy women undergoing reduction
mammoplasty (n = 23), or with pathological conditions
including fibroadenoma (n = 22), infiltrating ductal car-
cinoma (n = 23) and infiltrating lobular carcinoma (n =
23) were made available as FFPE archival material from
the Third Medical Faculty (Charles University, Prague,
Czech Republic). The original slides were re-evaluated
by a pathologist (DH) to confirm the initial pathology
diagnosis, and representative tissue blocks were selected
for further processing. Informed consent was obtained,
and the use of biopsy material for research was
approved by the Ethics Committee of the Third Medical
Faculty.
Tissue microarrays were constructed from routinely
prepared FFPE tissue blocks in parallel, using a manual
tissue arrayer TA1 (A Fintajsl, Czech Republic). The
representative area of interest was selected on the origi-
nal glass slide and corresponding area on donor tissue
block was inked. Tissue cylinders, 1.6 mm in diameter,
were punched from the marked regions of each donor
tissue block, and transferred to a recipient block for the
array. One hematoxylin and eosin section was made
from each block to ensure the presence of tumor
regions.
Scoring of positively stained regions was performed
with arbitrary establishment of a threshold for positive
IHC staining intensity. The scores consist of 0 = no
staining relative to no primary controls, 1 = weak diffuse
staining, 2 = moderate diffuse staining, 3 = strong
diffuse staining. Any focal staining present increased the
score by 1 (that is, a weakly diffuse stain with regions of
strong focal staining was scored a 2). Only the adenoma
or carcinoma compartment was scored, except in the
reduction mammoplasty group, where the entire section
was analyzed.
Statistics
Unless otherwise noted, all results are presented as
means +/- SEM. Paired t-tests were conducted on IHC
quantification and in vitro assays. Tumor incidence was
compared between WAP-Brk and wt mice using Fisher’s
exact test. Tumor latency was estimated using Kaplan-
Meier methodology and curves compared between
WAP-Brk and wt mice using the Wilcoxon test. A chi-
squared test was used to compare the association of
tumors staining positive for phospho-p38 MAPK with
tumors staining positive for Brk. All statistical tests were
conducted at a significance level of 0.05.
Results
The WAP-Brk transgene is expressed in the mammary
gland
To determine the effects of inducible Brk expression in
the normal mammary gland in vivo, a Brk cDNA encod-
ing the full-length wild-type protein kinase was put
under the control of the WAP promoter (Figure 1a),
which directs transgene expression predominantly to the
luminal epithelium in response to the hormones of
pregnancy and upon lactation [32]. Founders were gen-
erated and successfully bred to establish two indepen-
dent lines (Brk
83 and Brk
97); transgene presence was
verified by PCR (Figure 1b). Expression of Brk protein
was confirmed by both Western blotting of purified
mammary epithelial cells (MEC) and IHC analysis of
formalin fixed paraffin embedded (FFPE) mammary tis-
sues (Materials and methods). Total p38 MAPK, a ubi-
quitous member of the MAP kinase family, served as a
loading control in Western blotting (that is, of MEC
whole cell lysates) experiments. Total p38 levels were
somewhat lower in MEC purified from mammary glands
of both virgin and pregnant animals, but remained rela-
tively constant during involution Days 1 to 6. In lactat-
ing transgenic but not wild-type animals, Brk protein
expression was readily detectable at involution Day 1
(lactation Day 11) and this persisted to Day 6 of mam-
mary involution (Figure 1c). Brk expression was signifi-
cantly reduced (weakly detected) by Day 14 of
mammary involution; variable weak expression of Brk
also occurred in pregnant transgenic animals, but
remained consistently high during lactation (not shown).
IHC of FFPE tissues also demonstrated significant Brk
protein expression in mammary (luminal) epithelial cells
in both transgenic lines (Figure 1d); we designated these
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Page 4 of 17Figure 1 Transgene, screening and expression. A, Transgene (Tg) structure, including WAP promoter, beta-globin intron to enhance Tg
expression, Brk/PTK6 coding sequence, growth hormone poly A signal and BssHII restriction sites. B, PCR screening of founder mice and
controls. (L-R: purified construct, water, wild-type FVB, and two WAP-Brk founders.) C, Whole cell lysates from wild type and Brk
97 mammary
glands were subjected to Western blotting for Brk or total p38 MAPK, after enrichment for epithelial cells. D, Brk IHC in FFPE mammary gland
sections. Glands shown are from INV D1. Brown precipitate indicates positive staining. 200 × magnification.
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97 (founder
#11097) and Brk
83 (founder #8383). Brk was undetect-
able in wild-type controls by both protein detection
methods (Figure 1c, d).
WAP-Brk expression alters the kinetics of mammary gland
involution
Based on in vitro studies of Brk overexpression in HB4a
mammary epithelial cells [33], we hypothesized that Brk
may confer a proliferative and/or pro-survival phenotype
to normal MEC in vivo. Additionally, numerous studies
have demonstrated similar phenotypes upon expression
of human breast oncogenes in the mouse mammary
gland [34,35]. Therefore, we investigated whether Brk
expression in the mouse mammary gland resulted in
proliferative or inhibitory effects. Upon careful inspec-
tion of virgin and pregnant Brk transgenic mice (whole
mount analysis), we detected no noticeable differences
in mammary gland development (data not shown).
However, upon analysis of mammary glands undergoing
involution (Days 1 to 6), we noted that glands from Brk
transgenic mice were larger and had a higher cellular
content than their wild-type counterparts (Figure 2a).
Hematoxylin and eosin (H&E) staining of mammary
sections revealed a lag in remodeling of glands from Brk
transgenic mice relative to wild-type controls harvested
at the same stage of forced involution (Figure 2b).
A l v e o l ia tD a y1o fi n v o l u t i o ns h o w e dn om a j o rd i f f e r -
ences in development or milk content. However, glands
from Brk transgenic mice appeared to have fewer apop-
totic epithelial cells being shed into the lumen when
compared to matched wild-type animals. Notably, shed-
ding alveolar cells were still present in the lumen on
Day 4 of involution in mammary glands of Brk trans-
g e n i cm i c ew h e r e a sn o n ew e r ep r e s e n ti ng l a n d so f
wild-type mice. Additionally, there appeared to be larger
clusters of secretory alveoli in glands of transgenic mice
relative to wild-type animals (Day 4). By Day 6, glands
of both wild-type and Brk transgenic mice were mostly
repopulated with adipocytes, but Brk-transgenic mice
still exhibited functional alveoli, as indicated by the
noticeable presence of milk and lipid droplets within the
luminal spaces; ductal structures were distended and
filled with protein and lipid in the transgenic lines,
whereas in wild-type mice, ductal structures were col-
lapsed and adipocyte content returned to levels com-
monly observed for this time point during normal
murine mammary gland involution [36]. Days 9 and 14
of involution appeared similar in both wild-type and
transgenic lines, consistent with a decline in Brk trans-
gene expression at these late time points (not shown).
In order to quantify the epithelial content of mam-
mary glands from wild-type or Brk transgenic mice,
digital images of H&E sections were analyzed [34].
Using an arbitrary grid of 360 boxes overlaid onto an
image, the presence or absence of luminal epithelial
cells was recorded, and presented as a fraction of the
total grid (Figure 2c). Epithelial cell content did not dif-
fer during early (Days 1 to 3) involution. However,
beginning with Day 4 and significantly at Day 6, glands
from Brk transgenic animals presented with higher
epithelial content relative to same day wild-type glands;
these differences were resolved by Day 9. To validate
our analysis, the epithelial cell area was re-calculated by
arbitrarily selecting epithelial regions of mammary tissue
and determining the area of the selected regions (in pix-
els); these data are presented as a fraction of the whole
g l a n da tD a y6( i n s e tF i g u r e2 c ) .B r k
97 transgenic mice
Figure 2 WAP-Brk mammary glands exhibit delayed post-
lactational involution. A, Carmine alum staining of inguinal
mammary gland whole mounts, INV D6. B, H&E staining of inguinal
mammary glands from INV D1-INV D6. 200 × magnification. C,
Quantification of mammary epithelium from H&E sections, INV D1-
D14. Inset, epithelial content quantified by area on Day 6. Asterisks
signify statistically significant differences between groups (P < 0.05).
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epithelial cell area when compared to Day 6 wild-type
glands (3.6% versus 2.5%, P < 0.05). These data suggest
that Brk expression induces a delay in mammary gland
involution, which is most apparent between Days 4 and
6, and that mammary glands from transgenic mice
recover this difference by Days 9 to 14, consistent with
the decline in Brk expression by Day 14.
To further confirm a Brk-induced delay in mammary
gland involution (Figure 2), we investigated signaling
inputs associated with early initiation and execution of
involution. The first stage of involution (approximately
Days 1 to 3) is characterized by massive apoptosis and
luminal shedding of epithelial cell bodies formerly lining
the ducts [37]. To detect luminal epithelial cells under-
going apoptosis in glands from wild-type or Brk mice,
IHC was performed with antibodies directed against
cleaved caspase 3. Multiple representative images (Fig-
ure 3a, images) were scored for positive cells, with visi-
ble dead cells already shed into the lumen also being
counted as positive. Data are presented as the percen-
tage of cleaved caspase 3-positive cells relative to total
epithelial cells. At Day 4 of involution, fewer cleaved
caspase 3-positive cells were present in mammary glands
from transgenic mice relative to wild-type controls (Fig-
ure 3a, bar graph). By Day 6 of involution, apoptotic cell
numbers had reached similar levels in glands from both
Brk transgenic and wild-type animals. These results
were confirmed by TUNEL staining of apoptotic cells in
Day 4 glands (Figure 3b).
STAT3 is a critical mediator of the induction of involu-
tion [21,38]. Expression of STAT3 is required for mam-
mary involution, and in mouse models, its
phosphorylation is induced at the beginning of involution
but gradually declines over a six plus day time course
[21,38]. To directly measure STAT3 phosphorylation in
our Brk transgenic model, IHC was performed on wild-
type and Brk-expressing mammary glands during the
involution time course. Representative fields (Figure 4a)
from each time point were scored for the presence or
absence of p-STAT3 in individual cells of the luminal
epithelium, and presented as a percentage of total cell
count. The levels of p-STAT3 were similar in both lines
at involution Days 1 and 14. However, at Days 4 and 6,
glands from Brk transgenic animals exhibited roughly 10
to 20% less p-STAT3 relative to controls (Figure 4b). In
glands from WAP-Brk mice, the levels of p-STAT3
decreased precipitously from Days 1 to 4, compared to
the wild-type mice, in which the decrease was not evident
until Day 9. Similar to the epithelial content (Figure 2),
STAT3 signaling in glands from transgenic vs. wild-type
mice returned to comparable levels after Day 9, resulting
in an approximate 20% basal level of STAT3 phosphory-
lation in resting or fully regressed glands. Taken together,
these data support a Brk-dependent delay of early involu-
tion, as indicated by fewer apoptotic cells (Day 4); this
phenotype is associated with transient suppression of
STAT3 phosphorylation (Days 4 to 6), an independent
marker of involution induction. As with p-STAT3 (Figure
4b), mammary glands (InvD4) from WAP-Brk transgenic
mice contained slightly less p-STAT5 relative to mam-
mary glands from wt mice (not shown).
Brk expression promotes increased phosphorylation of
p38 MAPK
Previously, we reported that Brk promotes increased
breast cancer cell proliferation and migration in
Figure 3 Apoptotic events are decreased in mammary tissue
from WAP-Brk mice. A, Cleaved caspase 3 IHC. Images: INV D4 in
wild-type and Brk
97 mice, 400 × magnification. Graph: Quantification
of positive IHC staining, presented as a percentage of total
mammary epithelium. B, Quantification of Terminal
deoxynucleotidyl transferase mediated dUTP Nick End Labeling
(TUNEL) positive cells in INV D4 mammary gland sections.
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via Brk-dependent signaling to p38 MAPK [7]. Although
early studies initially described p38 MAPK as a mediator
of stress responses and linked to activation of apoptosis
pathways in multiple tissues, this kinase is closely asso-
ciated with pro-survival phenotypes in the context of
breast cancer [39]. We predicted that Brk-transgene
expression in the mammary gland may increase p38
MAPK activity, perhaps leading to prolonged luminal
epithelial cell survival and delayed involution (Figure 2).
FFPE sections from involuting mammary glands were
processed for phospho-p38 MAPK IHC (Figure 5a),
digitally analyzed and assigned H-scores (as above; see
Methods); data represent the degree of phospho-p38
Figure 4 Involution related STAT3 signaling decreases in WAP-Brk mice. A, Representative phospho-STAT3 IHC in involuting mammary
glands from INV D1-INV D6 wild-type and Brk
97 mice, 400 × magnification. B, Quantification of positive IHC staining, as a percentage of total
mammary epithelium. Asterisks signify statistically significant differences between groups (P < 0.05).
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Notably, at both Days 4 and 6 of involution, we detected
an approximately three-fold increase in the H-scores of
glands from Brk transgenic mice relative to glands from
same-day wild-type mice. Both the number of cells
staining for phospho-p38 and the intensity of staining
(per cell) were increased. These data suggest that Brk
can drive p38 MAPK signaling in vivo; activated p38
MAPK may act as a pro-survival signal in this setting,
leading to delayed mammary gland involution.
Brk-dependent signaling and pro-survival are linked
events in vitro
To further link Brk expression to activation of p38
MAPK in the mouse model, we introduced flag-tagged
Brk (Brk-Flag) or the Flag vector control (Flag) into Sik-
null HC11 murine mammary epithelial cells by transient
transfection and treated cells with the breast lactogen,
prolactin. p38 MAPK is abundantly expressed in these
cells. Following a time course of prolactin (500 ng/ml)
treatment, Western blotting revealed robust phosphory-
lation of p38 in both Flag-vector control and Brk-Flag
transfected cells (Figure 6a). However, in HC11 cells
expressing Brk-Flag, both the intensity (0 to 15 minutes)
and kinetics (see 15-minute time point) of p38 phos-
phorylation were increased relative to vector control
cells (Figure 6a). Notably, transient expression of Flag-
Brk in HC11 cells also induced increased basal p38
MAPK phosphorylation (that is, weak constitutive phos-
pho-p38 was repeatedly observed in the absence of
growth factors and hormones only in Flag-Brk expres-
sing cells). As a control for intact prolactin signaling
and Brk-dependent actions, we also blotted for phos-
phorylated STAT5, a known substrate of activated Brk
[19]. Similar to the published results of Weaver and
Silva [19] in breast cancer cells, we also observed Brk-
mediated regulation of p-STAT5 in vitro, but only in
prolactin-treated (5 to 30 minutes) cells (Figure 6a).
Phospho-STAT3 was not appreciably altered by these
treatments (not shown).
To further link Brk overexpression to activation of p38
MAPK, we made use of our previously engineered
human mammary epithelial cell (HMEC) lines stably
expressing either a vector control or wild-type Brk
(HMEC-Brk cells) [31]. Again, Brk expression alone
resulted in increased basal phosphorylation of p38 in
untreated cells (compare lanes 1 and 4); EGF-induced
activation of p38 was also slightly increased upon Brk
expression (15 to 30 minutes) relative to vector controls
(Figure 6b). Finally, EGF-dependent activation of p38
MAPK was effectively blocked (10 to 15 minutes) upon
knock-down (gene silencing) of endogenous Brk in Brk-
positive breast cancer cells (Figure 6c).
Recent in vitro studies have demonstrated that Brk
promotes anchorage independent survival [13]. To
address the biological effects of Brk overexpression in
an additional in vitro model of mammary epithelial cells,
we again made use of our HMEC lines stably expressing
either a vector control or wild-type Brk (HMEC-Brk
cells) [31]. These human cell lines and the mouse HC11
model (transiently transfected with vector or Flag-Brk as
above) were plated on PolyHEMA, a substrate that coats
plastic culture dishes and prevents cell attachment. Fol-
lowing 48 hrs, viable cells in suspension were counted
using Trypan Blue dye exclusion. Notably, Brk expres-
sion conferred increased anchorage independent survival
relative to vector controls in both HMEC and HC11
models (Figure 7a). Interestingly, Brk sensitized non-
transformed intestinal epithelial cells to apoptosis [40].
To further test the ability of Brk to alter the survival of
MEC, adherent cultures of HMEC cells stably expressing
either Brk or control vector were subjected to doxorubi-
cin, a commonly used cytotoxic (DNA damaging) agent.
A tad o s a g eo f0 . 1n g / m ld o x o r u b i c i n ,w ed e t e c t e dn o
significant difference between HMEC cells expressing
Brk and control cells, with approximately 80% of plated
cells remaining viable relative to vehicle-treated controls
Figure 5 Brk promotes p38 MAPK activation in mammary
glands. A, Phospho-specific p38 MAPK IHC in involuting mammary
glands, INV D4-INV D6. B, Quantification of positive IHC, presented
as an H-score (see Methods).
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ubicin treatment, only 25 to 30% of vector control cells
remained viable, whereas approximately 40% of Brk-
positive HMEC cells survived this treatment (relative to
vehicle controls). These data, together with published
findings in breast cancer cell models [13] suggest that
Brk expression confers a strong survival signal to both
normal and neoplastic mammary epithelial cells.
WAP-Brk mice develop adenosquamous carcinoma
Numerous in vitro s t u d i e ss u g g e s tt h a tB r ka c t sa sa
breast oncogene. However, this body of work has relied
Figure 6 Brk promotes p38 MAPK signaling in vitro. A, Brk expression sensitizes HC11 cells to prolactin treatment and increased basal p38
MAPK phosphorylation. Transiently transfected HC11 cells treated with 500 ng/mL prolactin were subjected to Western blotting for STAT5 and
p38 MAPK phosphorylation. B, Stable expression of Brk in HMEC increases basal p38 MAPK activation. C, Brk knockdown in T47D breast cancer
cells decreases EGF induced p38 MAPK phosphorylation. Whole cell lysates were subjected to Western blotting for p38 MAPK phosphorylation
and/or STAT5 phosphorylation.
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transformed and tumorigenic Brk-positive breast cancer
cell lines. Experiments expressing Brk in non-trans-
formed mammary epithelial cells usually include coop-
erating factors. For example, Kamalati et al. [33]
demonstrated Brk-induced soft-agar colony formation in
t h eE G F R - h i g hc e l ll i n eH B 4 a .C o e x p r e s s i o no fB r ka n d
ErbB2 in human (MCF-10A) or murine (Comma-1D)
mammary epithelial cells induced acinar disruption and
increased tumor growth, respectively [41]. To determine
if Brk expression acts as a potential singular oncogenic
insult in the mammary gland, we aged retired, multipar-
ous WAP-Brk and wild-type mice. Notably, mammary
tumors were infrequent events, but developed in multi-
parous WAP-Brk mice at a three-fold higher incidence
relative to wild-type mice (Table 1); this trend failed to
reach statistical significance. However, the tumor latency
significantly decreased (Table 1 and Figure 8a; Wilcoxon
P = 0.03). The pathology of mammary tumors arising in
Brk-transgenic mice consisted of duct-like structures
with squamous metaplasia filling the lumens, sur-
rounded by fibrotic stroma (Figure 8b). Keratin pearls
were often present (Figure 8b, arrows) in lesions where
the squamous metaplasia predominated. Large pleo-
m o r p h i cn u c l e iw e r ee v i d e n ti nt h e s er e g i o n s .H y p e r -
plastic ducts were also detected in nearby regions of
otherwise normal tissue architecture (Figure 8b). Brk
transgene expression was detected in mammary tumors
with strong cytoplasmic staining and sporadic nuclear
staining in hyperplastic ducts; weak cytoplasmic staining
occurred in cells that had undergone squamous meta-
plasia (Figure 8b).
Brk signaling intermediates are evident in human breast
biopsies
Although studies are limited, Brk appears to be
expressed in a majority of human breast cancers [6,7],
and is often co-expressed [42] or co-amplified [41] with
Her2. Using a human breast tumor tissue array, we
examined Brk co-expression with phospho-38 MAPK in
IHC-stained sections of normal breast tissue from
reduction mammoplasty (normal breast), fibroadenoma,
and infiltrating ductal or lobular carcinoma. Positively-
stained sections were further scored for intensity (by
pathological criteria) as defined in Materials and meth-
ods (Figure 9). Brk protein expression (Figure 9a) was
not detected in normal tissue samples (0/43), and
occurred in only one of 41 fibroadenoma samples. How-
ever, we detected Brk in 72.5% (29/40) of ductal carci-
noma samples and 52.2% (24/46) of lobular carcinomas
included in the array. These figures are in agreement
with our previous report of Brk expression in up to 86%
of mammary carcinoma (of 250 samples; [7]). Similar to
Brk expression, phospho-p38 MAPK (Figure 9b) was
absent from normal breast tissue. However, at least 30%
(12/40) of fibroadenoma, 17.9% of ductal samples (7/39),
and 37% of lobular carcinoma samples (17/46) stained
positively for phospho-p38 MAPK. Representative
images of staining intensities appear next to each bar
graph for each antibody used in the IHC analysis (Figure
9a, b).
We next examined the frequency of co-staining for
Brk and p-p38 within the same samples (Table 2). A
Figure 7 Brk promotes survival phenotypes in vitro. A,
Exogenous Brk expression in HMEC and HC11 cells promotes
anchorage independent survival. B, Brk expression in HMEC cells
provides partial resistance to doxorubicin. Cells were plated in
triplicate in three independent experiments; data shown are from
one representative experiment. Error bars represent +/- one
standard deviation.
Table 1 Tumor incidence in wild type vs.
Mouse line Tumor incidence Mean age of tumor bearing mice (days) Mean parity of tumor bearing mice
Wild Type 0.095 (2/21) 608 (552, 665) 3 litters (3)
Brk
83 0.300 (6/20) 316 (range: 150 to 453) 1.5 litters (range: 0 to 4)
transgenic mice
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samples that stained positive for Brk also co-stained
with phospho-p38 MAPK; Brk-positive tumors are 2.87
t i m e sm o r el i k e l yt ob ep h o s p h o - p 3 8 - p o s i t i v et h a nB r k -
null tumors are likely to be phospho-p38-positive (P =
.03). These data suggest that Brk is significantly asso-
ciated with activated p38 in breast cancer relative to
normal breast. Brk signaling to p38 MAPK may charac-
terize a subset (approximately 14 to 15%) of human
ductal and lobular breast carcinoma. More studies are
needed to fully understand the contribution of these
pathways (that is, Brk and p38 MAPK in combination)
to the development and maintenance or progression of
human breast carcinoma.
Discussion
H e r e i n ,w er e p o r tt h ef i r s tt r a n s g e n i cm o u s em o d e lo f
mammary specific (inducible) Brk expression (Figure 1).
Figure 8 WAP-Brk mice develop mammary tumors. A, Kaplan-Meier estimate for the tumor cohort desribed in Table 1 (tumor free mice vs.
days). B, Representative images of a tumor from WAP-Brk mouse B257. Left: H&E sections of a tumor in the R2 mammary gland. Right:
Transgene expression in the same tumor. (Arrow, keratin pearl; arrowhead: fibrotic stroma; h, hyperplastic duct; m, squamous metaplasia.)
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Page 12 of 17Figure 9 Brk-mediated signaling events are present in a human tissue array. A, Brk IHC in a human TMA. B, Phospho-p38 MAPK IHC in a
human TMA. Graphs: IHC intensity plotted as a fraction of all tissue samples on the array, totaling 100%. Images: Representative images of IHC
intensities in carcinoma samples. C, Brk and p-p38 MAPK co-staining in human TMA samples. Brk-positive tumors are 2.87 times more likely to be
phospho-p38-positive than Brk-null tumors are likely to be phospho-p38-positive (P = 0.03). The 95% CI for the odds ratio is (1.10, 7.43).
Table 2 Brk co-expression with p-p38 MAPK in human TMA samples
Tissue type Normal Fibroadenoma Ductal carcinoma Lobular carcinoma
Brk and p-p38 double positive 0/35 0/39 7/38 7/46
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lowing forced weaning (Figure 2). We detected evidence
of Brk-mediated signaling through increased phospho-
p38 MAPK (Days 4 and 6; Figure 5). Brk expression
also partially prevented anoikis in non-transformed
HMEC and HC11 cell lines in vitro (Figure 7a). Aged,
multiparous WAP-Brk mice exhibited a trend towards
higher tumor incidence and significantly decreased
tumor latency relative to wild-type mice (Table 1); these
tumors were Brk-positive (Figure 8b). Finally, we
detected significant association of phospho-p38 MAPK
in biopsies of Brk-positive human breast cancer (Figure
9 and Table 2). Our studies suggest that Brk confers
p38-associated pro-survival signals to non-transformed
(luminal) mammary epithelium. Given time, these events
m a yc o n s p i r et oi n d u c eo rp e r m i tt h ef o r m a t i o no f
latent mammary tumors (Figures 8 and 9).
Involution
Mouse mammary gland involution represents a highly
sensitive read-out of human oncogenic action; numerous
breast oncogenes induce delayed involution in mouse
models [26]. Similar to other models of mammary onco-
gene expression [34,35], our model undergoes delayed,
but ultimately complete mammary regression, highlight-
ing a distinct window of mammary signaling events
(Days 4 to 6 of involution) that are perturbed without
completely halting the involution process. We observed
fewer apoptotic figures, decreased caspase3 cleavage,
and reduced TUNEL staining in glands from WAP-Brk
transgenic mice, while clearance of apoptotic mammary
epithelial cells did not appear to be affected. Notably,
WAP-Brk transgenic mice eventually undergo complete
mammary regression, consistent with the decline of
WAP-driven Brk expression over the time course of
involution in this model. Upon multiple rounds of parity
induced mammary expansion and contraction, amplified
survival signaling may increase the chances for mam-
mary epithelial cells to encounter and fix potentially
oncogenic combinatorial events.
Tumor biology (in vivo model and human tumors)
Inducible Brk expression in our WAP-driven transgenic
model results in a tumorigenesis rate of 30% in aged
multiparous mice (Table 1 and Figure 8). Two wild-type
FVB mice from the same litter also developed tumors.
Indeed, this strain has a weak propensity to develop ade-
nosquamous mammary tumors at an advanced age [43].
Because of the sibling wild-type FVB tumors, the com-
parison of the number of tumors between wild-type and
Brk transgenic animals did not reach statistical signifi-
cance (P = 0.13). However, the age at tumor onset
decreased (Table 1) and this reduced tumor latency was
significantly different from wild-type controls (P = 0.03),
indicating an effect of Brk expression on the promotion
of tumorigenesis relative to wild-type FVB mice. Brk
strongly promotes breast cancer cell proliferation [7,44],
survival [13] and migration in vitro [7,14,44,45]. We did
not observe pulmonary metastatic lesions in tumor-
bearing WAP-Brk mice, suggesting that other cooperat-
ing factors are necessary for invasion and migration in
vivo. We are currently crossing WAP-Brk mice with
other mouse models of breast cancer in order to identify
additional oncogenic events that may cooperate with
Brk overexpression.
Brk protein is readily detectable in hyperplastic
regions of WAP-Brk mammary tumors (Figure 8b). The
loss of Brk protein in regions of squamous metaplasia of
WAP-Brk tumors is likely due to the loss of mammary
epithelial differentiation, an event(s) that may ultimately
lead to silencing the WAP promoter. Note that Brk
expression may drive the appearance of the squamous
metaplasia phenotype directly, as Brk expression in the
skin increases during the maturation of keratinocytes,
promoting squamous differentiation of the epidermis
[46].
Brk appears to predominantly mediate cellular survi-
val/resistance to involution-associated apoptosis in this
model. This phenotype is consistent with Brk-dependent
activation of p38 MAPK [7], as measured by its
increased phosphorylation (Figures 5 and 6). Elevated
phospho-p38 (Days 4 and 6) was detected in our involu-
tion time course experiments, in vitro experiments with
Brk-expressing HC11 cells, and in Brk-positive tumors
derived from both WAP-Brk mice (not shown) and
humans (Table 2 and Figure 9b). As expected, IHC ana-
lysis of the human breast tumor tissue array revealed
Brk expression in only one (a fibroadenoma) of the 84
non-transformed tissue samples (Figure 9a), and in Brk-
positive tumors, Brk expression was significantly asso-
ciated with increased phospho-p38 (Table 2); the sam-
ples in this group were mostly derived from
premenopausal women.
Brk mediated signals
The separation of normal physiological cues from trans-
gene-mediated signaling is critical to understanding
events that may contribute to mammary oncogenesis.
Initial characterization of WAP-Brk mammary glands
focused on STAT3 signaling as a marker of mammary
gland involution. STAT3 is a required mediator of invo-
lution-related cell death [21], and has been reported to
be a Brk substrate in studies using cell lines [18]. Our
IHC analysis illustrated that glands of WAP-Brk mice
contain less p-STAT3 during involution (Days 4 and 6)
relative to wild-type animals (Figure 4). These results
suggest that while Brk mediated STAT3 phosphorylation
may be relevant to the growth of established mammary
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sion of Brk does not appear to drive phospho-STAT3
during the initiation of involution. Similar to p-STAT3,
Brk expression in vivo also suppressed early (Day 4) p-
STAT5 levels; rapid loss of STAT5 phosphorylation,
characteristic of involution, occurred in both wt and
transgenic animals (data not shown). Thus, Brk does not
appear to be a positive regulator of STAT3 or STAT5 in
vivo; STAT3 phosphorylation may serve primarily as an
indicator of the progress of mammary involution herein.
Other factors (not addressed herein) that may contribute
to Brk-dependent pro-survival include amplification of
signaling pathways downstream of erbB family members
[33,48], including activation of ERK5 signaling [7,45].
These pathways are frequently associated with breast
cancer progression and invasive tumor behavior [49,50].
We have previously described Brk mediated p38
MAPK signaling as primarily promoting cell migration
in EGF or heregulin-treated breast cancer cell lines [7].
However, there are limited studies investigating the role
of p38 MAPK activity in mouse models of breast can-
cer. Demidov et al. [51] expressed an MMTV-driven
active MKK6 (an upstream kinase in the p38 MAPK
module), and showed resistance to development of
ErbB2 and Wip1 induced mammary tumors; however,
when overexpressed, MKK6 may regulate other MAPKs
[52]. Similar to our studies, Leung et al. [35] expressed
MMTV-V12Rac3 and described incomplete involution
associated with elevated phospho-p38 MAPK. Addition-
ally, Wang et al. [53] overexpressed activated Pak1
under the b-lactoglobin promoter and reported a 20%
tumorigenesis rate and elevated phospho-p38 MAPK. In
both of these studies, as well as ours, there were detect-
able levels of phospho-p38 in wild-type cohorts, strongly
suggesting an as of yet under appreciated physiological
role for p38 MAPK in mammary gland biology. Mam-
mary glands from WAP-Brk transgenic mice exhibited
higher phospho-p38 levels relative to wild-type glands
during Days 4 and 6 of the involution time course (Fig-
ure 5), again consistent with an increased survival sti-
mulus in WAP-Brk mice. Interestingly, expression of
Brk in HC11 or HMEC cells increased basal phospho-
p38 in serum-starved cells (Figure 6), indicating that the
presence of Brk is sufficient to promote p38 MAPK
activation and survival of mammary epithelium. These
data suggest that p38 phosphorylation induced by Brk
expression in non-transformed mammary epithelium
could contribute to breast disease as either an early
event (allowing pro-survival and/or luminal filling) or
late event (migration/dissemination, therapy resistance)
in tumorigenesis, thereby leading to a poor prognosis.
Recent literature [13] and our observations in HMEC
and HC11 cell lines (Figure 7) illustrate that Brk pro-
motes anchorage independent survival. Importantly, this
has been shown to be a p38 MAPK-dependent pheno-
type in Brk-positive MDA-MB-468 cells [54]. Taken
together, these data suggest that Brk-mediated p38 acti-
vation is likely a critical node for mammary epithelial
cell pro-survival and relevant to early oncogenic signal-
ing; p38 inhibitors may present an opportunity for ther-
apeutic intervention aimed at long term breast cancer
prevention and/or increased sensitivity to chemothera-
peutic agents.
Conclusions
This study characterizes the first mouse model of mam-
mary gland specific Brk/PTK6 expression, and identifies
Brk-dependent signaling pathways associated with pro-
survival (p38 MAPK). Brk/PTK6 expression in non-
transformed mammary epithelium causes delayed invo-
lution and promotes early tumorigenesis in aged mice,
with signaling that recapitulates the same altered signal-
ing pathways present in human tumor biopsies. The
identification of Brk-dependent signaling events reveals
potential therapeutic targets (Brk, p38 MAPK) for Brk-
positive breast cancers.
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